向体新陈代谢,缓解凝胺耐药性的作用
Krizia Rohena-Rivera1,2, Sungyong You2,3,4, Minhyung Kim3
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
JCI insight
|November 7, 2024
概括
代谢酶OXCT1通过改变细胞代谢和促进干细胞分化,驱动膀癌 (BCa) 中的凝素耐药性. 向OXCT1可能会恢复BCa患者的化疗敏感性.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 膀癌 (BCa) 治疗通常涉及化疗和手术,但复发率仍然很高 (70%在5年内).
- 代谢重编程越来越被认为是癌症化学抵抗的一个关键因素.
- 了解耐药机制对于改善BCa治疗结果至关重要.
研究的目的:
- 为了研究代谢酶OXCT1在膀癌中耐 gemcitabine 耐药性的作用.
- 阐明OXCT1对抗化学物质产生作用的潜在机制.
- 确定潜在的治疗点,以克服BCa.中的凝胺耐药性.
主要方法:
- 分析肌肉侵入性BCa和耐化学药患者队列中的OXCT1表达.
- 在小鼠中测试了正位素瘤模型,以评估OXCT1.1的影响.
- 对OXCT1进行基因操纵 (Knockout) 并使用β-基酸盐 (βHB) 类反体.
- 多omics分析 (转录组学,蛋白质组学) 以确定下游效应因素.
- 调查OVOL1作为转录调节者的作用.
主要成果:
- 在肌肉侵入性BCa和耐化学药性瘤中,OXCT1水平升高.
- 通过OXCT1的淘汰,恢复了对gemcitabine的敏感性,并逆转了代谢重编程.
- OXCT1促进了线粒体活动,ATP生产和核酸生物合成.
- OXCT1调节了转录抑制剂OVOL1,影响了表皮分化和预后.
- 通过代谢和癌症干细胞分化,OXCT1调解了凝素敏感性.
结论:
- 在膀癌中,OXCT1是凝抗药的关键媒介.
- OXCT1的作用超越了新陈代谢,影响了OVOL1介导的分化.
- 向OXCT1是一个潜在的策略,可以提高BCa.的化疗疗效果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
09:56Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
9.1K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
